GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (OTCPK:GLAXF) » Definitions » Cyclically Adjusted PS Ratio

GSK (GLAXF) Cyclically Adjusted PS Ratio : 1.66 (As of Apr. 27, 2025)


View and export this data going back to . Start your Free Trial

What is GSK Cyclically Adjusted PS Ratio?

As of today (2025-04-27), GSK's current share price is $17.976. GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was $10.83. GSK's Cyclically Adjusted PS Ratio for today is 1.66.

The historical rank and industry rank for GSK's Cyclically Adjusted PS Ratio or its related term are showing as below:

GLAXF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.49   Med: 2.02   Max: 2.5
Current: 1.6

During the past years, GSK's highest Cyclically Adjusted PS Ratio was 2.50. The lowest was 1.49. And the median was 2.02.

GLAXF's Cyclically Adjusted PS Ratio is ranked better than
60.25% of 732 companies
in the Drug Manufacturers industry
Industry Median: 2.015 vs GLAXF: 1.60

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GSK's adjusted revenue per share data for the three months ended in Dec. 2024 was $2.469. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $10.83 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


GSK Cyclically Adjusted PS Ratio Historical Data

The historical data trend for GSK's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted PS Ratio Chart

GSK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.82 2.11 1.75 1.72 1.55

GSK Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 2.02 1.79 1.77 1.55

Competitive Comparison of GSK's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.


;
;

GSK Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

GSK's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=17.976/10.83
=1.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, GSK's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=2.469/135.1000*135.1000
=2.469

Current CPI (Dec. 2024) = 135.1000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 2.161 99.600 2.931
201506 2.352 100.100 3.174
201509 2.409 100.200 3.248
201512 2.384 100.400 3.208
201603 2.268 100.400 3.052
201606 2.387 101.000 3.193
201609 2.527 101.500 3.364
201612 2.388 102.200 3.157
201703 2.317 102.700 3.048
201706 2.397 103.500 3.129
201709 2.649 104.300 3.431
201712 2.575 105.000 3.313
201803 2.550 105.100 3.278
201806 2.449 105.900 3.124
201809 2.659 106.600 3.370
201812 2.601 107.100 3.281
201903 2.535 107.000 3.201
201906 2.479 107.900 3.104
201909 2.900 108.400 3.614
201912 2.881 108.500 3.587
202003 2.807 108.600 3.492
202006 2.375 108.800 2.949
202009 2.778 109.200 3.437
202012 -0.335 109.400 -0.414
202103 2.553 109.700 3.144
202106 2.028 111.400 2.459
202109 2.245 112.400 2.698
202112 2.317 114.700 2.729
202203 2.330 116.500 2.702
202206 1.680 120.500 1.884
202209 2.169 122.300 2.396
202212 2.197 125.300 2.369
202303 2.065 126.800 2.200
202306 2.214 129.400 2.312
202309 2.452 130.100 2.546
202312 2.474 130.500 2.561
202403 2.275 131.600 2.336
202406 2.433 133.000 2.471
202409 2.559 133.500 2.590
202412 2.469 135.100 2.469

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GSK  (OTCPK:GLAXF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


GSK Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK Business Description

Industry
Address
79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.